An open-label phase 2 study has shown that canakinumab--which binds selectively to IL-1β, thus potently inhibiting its activity--produces rapid, complete, and sustained responses in adults and children with CAPS [5]. The gene discussed is IL1B; the disease is cryopyrin-associated periodic syndrome.